Who is sponsoring NCT03535220?

NCT03535220 is sponsored by American Society of Hematology.

What drugs are being tested in NCT03535220?

Interventions in NCT03535220: Protease Inhibitors.

What condition does NCT03535220 study?

NCT03535220 studies Benign and Malignant Hematologic Diseases.

Is NCT03535220 still recruiting?

NCT03535220 is currently status unknown. Last updated 24 May 2018.

Last reviewed 2018-05-24 · How we verify

NCT03535220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Status unknown Last updated 24 May 2018

What this trial tests

trial testing Protease Inhibitors in Benign and Malignant Hematologic Diseases in 20,000 participants. Status unknown.

Timeline

10 May 2018

Primary endpoint
31 December 2023

31 January 2025

Quick facts

Lead sponsor	American Society of Hematology
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20,000
Start date	10 May 2018
Primary completion	31 December 2023
Estimated completion	31 January 2025
Sites	1 location across United States

Drugs / interventions tested

Protease Inhibitors — full drug profile →

Conditions studied

Benign and Malignant Hematologic Diseases — all drugs for Benign and Malignant Hematologic Diseases →

Sponsor

American Society of Hematology

Who can join

Adults 1 to 65, any sex, with Benign and Malignant Hematologic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, retrospective and prospective, long-term registry of patients with benign or malignant hematologic diseases, whether or not these patients were or were not treated with disease-specific treatments. Information will be collected on patient demographics, disease characteristics, genomic and molecular data, laboratory data, pathology, radiographic reports, clinical status, quality of life, medications, and dosing information. Where appropriate, these data structures may be based on a combination of Fast Healthcare Interoperability Resources (FHIR) , Consolidated-Clinical Data Architecture (C-CDA) and/or client-speciﬁc structure deﬁnitions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03535220 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by American Society of Hematology
Last refreshed: 24 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03535220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing